Dynavax Technologies (NASDAQ:DVAX) Hits New 12-Month Low at $10.48

Dynavax Technologies Co. (NASDAQ:DVAX)’s stock price hit a new 52-week low during mid-day trading on Thursday . The company traded as low as $10.48 and last traded at $11.00, with a volume of 396747 shares changing hands. The stock had previously closed at $11.65.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on DVAX shares. The Goldman Sachs Group started coverage on shares of Dynavax Technologies in a research note on Thursday, February 1st. They issued a “neutral” rating and a $20.00 price objective for the company. HC Wainwright reiterated a “buy” rating and issued a $29.00 target price on shares of Dynavax Technologies in a report on Thursday. StockNews.com downgraded shares of Dynavax Technologies from a “buy” rating to a “hold” rating in a report on Friday, April 26th. Finally, William Blair restated an “outperform” rating on shares of Dynavax Technologies in a report on Friday, February 23rd. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $25.33.

Dynavax Technologies Stock Down 5.2 %

The company has a debt-to-equity ratio of 0.41, a quick ratio of 12.96 and a current ratio of 13.81. The firm’s fifty day moving average is $12.06 and its 200 day moving average is $13.03. The firm has a market cap of $1.44 billion, a P/E ratio of -194.17 and a beta of 1.30.

Insider Buying and Selling

In other news, CAO Justin Burgess sold 20,526 shares of the stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $12.78, for a total value of $262,322.28. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 2.98% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Dynavax Technologies

A number of hedge funds have recently bought and sold shares of the business. DekaBank Deutsche Girozentrale purchased a new stake in shares of Dynavax Technologies during the 3rd quarter valued at about $33,000. Advisor Resource Council bought a new position in shares of Dynavax Technologies during the 4th quarter valued at approximately $144,000. Rathbones Group PLC bought a new position in shares of Dynavax Technologies during the 3rd quarter valued at approximately $158,000. China Universal Asset Management Co. Ltd. bought a new position in shares of Dynavax Technologies during the 4th quarter valued at approximately $209,000. Finally, Duality Advisers LP bought a new position in shares of Dynavax Technologies during the 1st quarter valued at approximately $227,000. Hedge funds and other institutional investors own 96.96% of the company’s stock.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.